Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by MSD .
Filed returns
162
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Jan–Apr 2024 | MSD | Health | The importance of predictability in IP rights in the EU Pharmaceutical Legislation revision (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2024 | MSD | Health | Meetings to highlight the importance of predictability in IP rights in EU Pharmaceutical Legislation revision (Legislation) | 5 | On lobbying.ie |
| Jan–Apr 2024 | MSD | Health | Meeting to discuss pharma industry in Ireland and importance of (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2023 | MSD | Health | Early detection and treatment of cancer (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2023 | MSD | Health | Access to Innovative Medicines (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2023 | MSD | Health | Access to Innovative Medicines (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2023 | MSD | Health | New medicines funding in Budget 2024 (Public policy or programme) | 7 | On lobbying.ie |
| Sep–Dec 2023 | MSD | Health | Continued importance of a competitive and favorable business environment in Ireland (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2023 | MSD | Health | Positioning Ireland in the Global Biopharmaceutical Industry (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2023 | MSD | Health | National Immunisation programme (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2023 | MSD | Health | To highlight problems in Ireland faced by patients with TNBC and policy areas that need focus. (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2023 | MSD | Health | New medicines funding in Budget 2024 (Public policy or programme) | 7 | On lobbying.ie |
| Sep–Dec 2023 | MSD | Health | New medicines Funding in Budget 2024 (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2023 | MSD | Health | Vaccination programmes (Matters involving public funds) | 3 | On lobbying.ie |
| May–Aug 2023 | MSD | Health | Access to innovative cancer medicines (Public policy or programme) | 7 | On lobbying.ie |
| May–Aug 2023 | MSD | Health | Early detection and treatment of cancer (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2023 | MSD | Health | EU Pharmaceutical Legislation (Legislation) | 7 | On lobbying.ie |
| Jan–Apr 2023 | MSD | Agriculture | Policy: TAMS grants for Monitoring Technology (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2023 | MSD | Agriculture | Hosted by Colm Markey MEP in Brussels to discuss the position of agtech in Ireland and Europe’s ecosystem. AgTech Ireland is the first EU organisation dedicated to the agtech needs of an EU member state. The topics… (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2023 | MSD | Health | Reimbursement of innovative medicines and vaccines (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2023 | MSD | Health | Revision of the European Pharmaceutical Legislation (Public policy or programme) | 17 | On lobbying.ie |
| Jan–Apr 2023 | MSD | Health | Early detection and treatment of cancer (Public policy or programme) | 11 | On lobbying.ie |
| Sep–Dec 2022 | MSD | Agriculture | Animal Health and Technology (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2022 | MSD | Finance | Taxation and Foreign Direct Investment (Legislation) | 2 | On lobbying.ie |
| Sep–Dec 2022 | MSD | Economic Development and Industry | Positioning Ireland in the Global Biopharmaceutical Industry (Public policy or programme) | 7 | On lobbying.ie |
| Sep–Dec 2022 | MSD | Health | Immunisation Policies (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2022 | MSD | Health | Early detection and treatment of cancer (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2022 | MSD | Health | EU Pharmaceutical Legislation (Legislation) | 1 | On lobbying.ie |
| Sep–Dec 2022 | MSD | Health | Reimbursement of innovative oncology medicines and establishment of a National Medicines Agency (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2022 | MSD | Health | Launch of research report on socio-economic inequalities in cancer (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2022 | MSD | Health | Access to Medicines (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2022 | MSD | Economic Development and Industry | Positioning Ireland in the Global Biopharmaceutical Industry (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2022 | MSD | Agriculture | Livestock Farming (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2022 | MSD | Health | Oncology Policy (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2022 | MSD | Health | Immunisation Policies (Public policy or programme) | 7 | On lobbying.ie |
| Sep–Dec 2021 | MSD | Health | Policy Priorities in a post-pandemic COVID-19 era (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2021 | MSD | Health | Immunisation Policies (Public policy or programme) | 26 | On lobbying.ie |
| Sep–Dec 2021 | MSD | Health | Oncology Policy (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2021 | MSD | Health | Cancer Care in a post-pandemic COVID-19 era (Public policy or programme) | 15 | On lobbying.ie |
| May–Aug 2021 | MSD | Health | Oncology Data Policy (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2021 | MSD | Health | Cancer Care in a post-pandemic COVID-19 era (Public policy or programme) | 18 | On lobbying.ie |
| May–Aug 2021 | MSD | Health | Immunisation Policies (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2021 | MSD | Health | Policy Priorities in a post-pandemic COVID-19 era (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2021 | MSD | Health | Oncology Policy (Public policy or programme) | 9 | On lobbying.ie |
| Jan–Apr 2021 | MSD | Health | Immunisation Policies (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2020 | MSD | Health | Policy Priorities in a post-pandemic COVID-19 era (Public policy or programme) | 26 | On lobbying.ie |
| Sep–Dec 2020 | MSD | Health | Oncology Policy (Public policy or programme) | 34 | On lobbying.ie |
| Sep–Dec 2020 | MSD | Economic Development and Industry | Positioning Ireland in the Biopharmaceutical Industry (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2020 | MSD | Health | Immunisation Policies (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2020 | MSD | Health | Oncology Policy (Public policy or programme) | 4 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 118 | 72.8% | |
| Economic Development and Industry | 26 | 16.0% | |
| EU Affairs | 5 | 3.1% | |
| Agriculture | 4 | 2.5% | |
| Education and Training | 2 | 1.2% | |
| Energy and Natural Resources | 2 | 1.2% | |
| Finance | 2 | 1.2% | |
| Communications | 1 | 0.6% | |
| Foreign Affairs | 1 | 0.6% | |
| Transport | 1 | 0.6% |